Emapalumab for the treatment of refractory cytokine release syndrome in pediatric patients

Blood Adv. 2023 Sep 26;7(18):5603-5607. doi: 10.1182/bloodadvances.2023010712.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Letter

MeSH terms

  • Antibodies, Monoclonal* / adverse effects
  • Antibodies, Neutralizing
  • Child
  • Cytokine Release Syndrome* / drug therapy
  • Cytokine Release Syndrome* / etiology
  • Humans

Substances

  • Emapalumab
  • Antibodies, Monoclonal
  • Antibodies, Neutralizing